Sucampo Pharmaceuticals — Investor Presentation (February 2014)
5 slides from Sucampo Pharmaceuticals's investor presentation, Feb 12, 2014
Slide 1: Leadership Transition
Leadership Transition Peter Greenleaf named new Sucampo CEO effective March 3, 2013 + 20 years of biopharma experience in commercialization & drug development + Current CEO and Director of Histogenix, former President of MedImmune, the worldwide biologics R&D arm of AstraZeneca Dan Getman, Ph.D. app
Slide 2: AMITIZA U.S. Market Growth Accelerating
AMITIZA U.S. Market Growth Accelerating * Class up 5% YoY' Continued AMITIZA YOY Growth + Takeda reported Q3 net sales at $72.5M*; 3.5% YoY increase in net sales to $204M through September + AMITIZA TRx up 4% YoY through December YTD"; Q4 highest TRx quarter ever recorded and overall calendar year h
Slide 3: Key Facts & Financial Highlights
Key Facts & Financial Highlights Trading Symbol SCMP (NASDAQ) Corporate Headquarters Bethesda, MD Stock Price (02-10-14), 52-Week Range $7.78, $11.00 to $4.55 Shares Outstanding (12-31-13) 43.5M (1 class of common stock) Daily Volume (90-day average) 193,241 Market C (02-10-14) $338.6M Enterprise Va
Slide 4: Additional Key Upcoming Events
Additional Key Upcoming Events Commercial AMITIZA OIC indication potential approval in Switzerland / U.K. Clinical End of P3 lubiprostone liquid formulation study End of P'1b study in cobiprostone for oral mucositis Start of Phase 1b study for oral ion channel activator in LSS Pediatric lubiprostone
Slide 5: Key Facts & Financial Highlights
Key Facts & Financial Highlights Key Facts Trading Symbol SCMP (NASDAQ) ncial High 9 Months of hts as of 2013 Corporate Headquarters | Bethesda, MD Debt $57.9M Stock Price (02-10-14), 52. | $7.78, $11.00 to Cash & Equivalents $91.0M Week Range $4.55 Total Operating Expense | $49.1M Shares Outstandin
Sucampo Pharmaceuticals — Investor Presentation (February 2014) on 6ix